Adeno-Associated Virus-Mediated Gene Delivery

Journal of Gene Medicine

Volumn 1, Issue 3, 1999, Pages 166-175

  Snyder, Richard O ^a,b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

AAV; Adeno associated virus; Gene therapy; Gene transfer; Integration; Transduction

Indexed keywords

ADENO-ASSOCIATED VIRUS; ANIMALIA;

ADENO ASSOCIATED VIRUS; ANIMAL; BIOTECHNOLOGY; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC ENGINEERING; GENETIC RECOMBINATION; GENETICS; HUMAN; REVIEW;

ANIMALS; BIOTECHNOLOGY; DEPENDOVIRUS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; RECOMBINATION, GENETIC;

EID: 0033122032     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1521-2254(199905/06)1:3<166::aid-jgm34>3.0.co;2-z     Document Type: Review

References (149)

1. Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science 1965; 194: 754-756.
2. Hermonat PL, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci U S A 1984; 81: 6466-6470.
3. Tratschin JD, West MH, Sandbank T, Carter BJ. A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol Cell Biol 1984; 4: 2072-2081.
4. Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol 1983; 45: 555-5564.
5. Samulski RJ, Berns KI, Tan M, Muzyczka N. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A 1982; 79: 2077-2081.
6. Tratschin JD, Miller IL, Carter BJ. Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function. J Virol 1984; 51: 611-619.
7. Hermonat PL, Labow MA, Wright R, Berns KI, Muzyczka N. Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants. J Virol 1984; 51: 329-339.
8. Im DS, Muzyczka N. The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity. Cell 1990; 61: 447-457.
9. Owens RA, Weitzman MD, Kyostio SR, Carter BJ. Identification of a DNA-binding domain in the amino terminus of adeno-associated virus Rep proteins. J Virol 1993; 67: 997-1005.
10. Smith RH, Spano AJ, Kotin RM. The Rep78 gene product of adeno-associated virus (AAV) self-associates to form a hexameric complex in the presence of AAV ori sequences. J Virol 1997; 71: 4461-4471.
11. Labow MA, Hermonat PL, Berns KI. Positive and negative autoregulation of the adeno-associated virus type 2 genome. J Virol 1986; 60: 251-258.
12. McCarty DM, Christensen M, Muzyczka N. Sequences required for coordinate induction of adeno-associated virus p19 and p40 promoters by Rep protein. J Virol 1991; 65: 2936-2945.
13. Horer M, Weger S, Butz K, Hoppe-Seyler F, Geisen C, Kleinschmidt JA. Mutational analysis of adeno-associated virus Rep protein-mediated inhibition of heterologous and homologous promoters. J Virol 1995; 69: 5485-5496.
14. Weitzman MD, Kyostio SR, Kotin RM, Owens RA. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci U S A 1994; 91: 5808-5812.
15. Chejanovsky N, Carter BJ. Mutagenesis of an AUG codon in the adeno-associated virus rep gene: effects on viral DNA replication. Virology 1989; 173: 120-128.
16. Smith RH, Kotin RM. The Rep52 gene product of adeno-associated virus is a DNA helicase with 3′-to-5′ polarity. J Virol 1998; 72: 4874-4881.
17. Pereira DJ, McCarty DM, Muzyczka N. The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection. J Virol 1997; 71: 1079-1088.
18. Di Pasquale G, Stacey SN. Adeno-associated virus Rep78 protein interacts with protein kinase A and its homolog PRKX and inhibits CREB-dependent transcriptional activation. J Virol 1998; 72: 7916-7925.
19. Chiorini JA, Zimmermann B, Yang L, et al. Inhibition of PrKX, a novel protein kinase, and the cyclic AMP-dependent protein kinase PKA by the regulatory proteins of adeno-associated virus type 2. Mol Cell Biol 1998; 18: 5921-5929.
20. Weger S, Wendland M, Kleinschmidt JA, Heilbronn R. The Adeno-Associated Virus Type 2 Regulatory Proteins Rep78 and Rep68 Interact with the Transcriptional Coactivator PC4. J Virol 1999; 73: 260-269.
21. Pereira DJ, Muzyczka N. The cellular transcription factor SP1 and an unknown cellular protein are required to mediate Rep protein activation of the adeno-associated virus p19 promoter. J Virol 1997; 71: 1747-1756.
22. McLaughlin SK, Collis P, Hermonat PL, Muzyczka N. Adeno-associated virus general transduction vectors: analysis of proviral structures. J Virol 1988; 62: 1963-1973.
23. Cavalier-Smith T. Palindromic base sequences and replication of eukaryote chromosome ends. Nature 1974; 250: 467-470.
24. Snyder RO, Im DS, Muzyczka N. Evidence for covalent attachment of the adeno-associated virus (AAV) rep protein to the ends of the AAV genome. J Virol 1990; 64: 6204-6213.
25. Costello E, Saudan P, Winocour E, Pizer L, Beard P. High mobility group chromosomal protein 1 binds to the adeno-associated virus replication protein (Rep) and promotes Rep-mediated site-specific cleavage of DNA, ATPase activity and transcriptional repression. EMBO J 1997; 16: 5943-5954.
26. Ward P, Dean FB, O'Donnell ME, Berns KI. Role of the adenovirus DNA-binding protein in in vitro adeno-associated virus DNA replication. J Virol 1998; 72: 420-427.
27. Ni TH, McDonald WF, Zolotukhin I, et al. Cellular proteins required for adeno-associated virus DNA replication in the absence of adenovirus coinfection. J Virol 1998; 72: 2777-2787.
28. Redemann BE, Mendelson E, Carter BJ. Adeno-associated virus rep protein synthesis during productive infection. J Virol 1989; 63: 873-882.
29. Carter BJ. The growth cycle of Adeno-associated virus. In Handbook of Parvoviruses, vol. 1, In: Tijssen P (ed). Boca Raton: CRC Press, 1990; 155-168.
30. Richardson WD, Westphal H. A cascade of adenovirus early functions is required for expression of adeno-associated virus. Cell 1981; 27: 133-141.
31. Shi Y, Seto E, Chang LS, Shenk T. Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell 1991; 67: 377-388.
32. Pilder S, Moore M, Logan J, Shenk T. The adenovirus E1B-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs. Mol Cell Biol 1986; 6: 470-476.
33. Jay FT, Laughlin CA, Carter BJ. Eukaryotic translational control: adeno-associated virus protein synthesis is affected by a mutation in the adenovirus DNA-binding protein. Proc Natl Acad Sci U S A 1981; 78: 2927-2931.
34. Chang LS, Shenk T. The adenovirus DNA-binding protein stimulates the rate of transcription directed by adenovirus and adeno-associated virus promoters. J Virol 1990; 64: 21039.
35. Janik JE, Huston MM, Cho K, Rose JA. Efficient synthesis of adeno-associated virus structural proteins requires both adenovirus DNA binding protein and VA I RNA. Virology 1989; 168: 320-329.
36. Weindler FW, Heilbronn R. A subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication. J Virol 1991; 65: 2476-2483.
37. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438-1445.
38. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 [In Process Citation]. Nat Med 1999; 5: 71-77.
39. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection [In Process Citation]. Nat Med 1999; 5: 78-82.
40. Rutledge EA, Halbert CL, Russell DW. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol 1998; 72: 309-319.
41. Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989; 63: 3822-3828.
42. Snyder RO, Xiao X, Samulski RJ. Production of Recombinant Adeno-Associated Viral Vectors. In Current Protocols in Human Genetics, In: Dracopoli N, Haines J, Krof B, et al. (eds). New York: John Wiley and Sons, 1996; 12.1.1-24.
43. Gottlieb J, Muzyczka N. In vitro excision of adeno-associated virus DNA from recombinant plasmids: isolation of an enzyme fraction from HeLa cells that cleaves DNA at poly(G) sequences. Mol Cell Biol 1988; 8: 2513-2522.
44. Xiao X, Xiao W, Li J, Samulski RJ. A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J Virol 1997; 71: 941-948.
45. Li J, Samulski RJ, Xiao X. Role for highly regulated rep gene expression in adeno-associated virus vector production. J Virol 1997; 71: 5236-5243.
46. Vincent KA, Piraino ST, Wadsworth SC. Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products. J Virol 1997; 71: 1897-1905.
47. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adenoassociated virus vectors [In Process Citation]. Hum Gene Ther 1998; 9: 2745-2760.
48. Wang XS, Ponnazhagan S, Srivastava A. Rescue and replication of adeno-associated virus type 2 as well as vector DNA sequences from recombinant plasmids containing deletions in the viral inverted terminal repeats: selective encapsidation of viral genomes in progeny virions. J Virol 1996; 70: 1668-1677.
49. Cotmore SF, Christensen J, Nuesch JP, Tattersall P. The NS1 polypeptide of the murine parvovirus minute virus of mice binds to DNA sequences containing the motif [ACCA]2-3. J Virol 1995; 69: 1652-1660.
50. Hunter LA, Samulski RJ. Colocalization of adeno-associated virus Rep and capsid proteins in the nuclei of infected cells. J Virol 1992; 66: 317-324.
51. Wistuba A, Kern A, Weger S, Grimm D, Kleinschmidt JA. Subcellular compartmentalization of adeno-associated virus type 2 assembly. J Virol 1997; 71: 1341-1352.
52. Ding L, Lu S, Munshi NC. In vitro packaging of an infectious recombinant adeno-associated virus 2. Gene Ther 1997; 4: 1167-1172.
53. Zhou X, Muzyczka N. In vitro packaging of adeno-associated virus DNA. J Virol 1998; 72: 3241-3247.
54. Clark KR, Voulgaropoulou F, Johnson PR. A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Ther 1996; 3: 1124-1132.
55. Gao GP, Qu G, Faust LZ, et al. High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus [In Process Citation]. Hum Gene Ther 1998; 9: 2353-2362.
56. Inoue N, Russell DW. Packaging Cells Based on Inducible Gene Amplification for the Production of Adeno-Associated Virus Vectors. J Virol 1998; 72: 7024-7031.
57. Yang Q, Chen F, Trempe JP. Characterization of cell lines that inducibly express the adeno-associated virus Rep proteins. J Virol 1994; 68: 4847-4856.
58. Legendre D, Rommelaere J. Terminal regions of the NS-1 protein of the parvovirus minute virus of mice are involved in cytotoxicity and promoter trans inhibition. J Virol 1992; 66: 5705-5713.
59. Wang XS, Khuntirat B, Qing K, et al. Characterization of wild-type adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their elimination. J Virol 1998; 72: 547280.
60. Allen JM, Debelak DJ, Reynolds TC, Miller AD. Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by non-homologous recombination during AAV vector production. J Virol 1997; 71: 6816-6822.
61. Salvetti A, Oreve S, Chadeuf G, et al. Factors influencing recombinant adeno-associated virus production. Hum Gene Ther 1998; 9: 695-706.
62. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70: 3227-3234.
63. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.
64. Thrasher AJ, de Alwis M, Casimir CM, et al. Generation of recombinant adeno-associated virus (rAAV) from an adenoviral vector and functional reconstitution of the NADPH-oxidase. Gene Ther 1995; 2: 481-485.
65. Fisher KJ, Kelley WM, Burda JF, Wilson JM. A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum Gene Ther 1996; 7: 2079-2087.
66. Conway JE, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J Virol 1997; 71: 8780-8789.
67. Johnston KM, Jacoby D, Pechan PA, et al. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum Gene Ther 1997; 8: 359-370.
68. Conway JE, et al. Efficient recombinant AAV vector production using novel herpes vectors. Gene Ther 1999; in press.
69. Arella M, Garzon S, Bergeron J, Tijssen P. Physiochemical Properties, Production, and Purification of Parvoviruses. In Handbook of Parvoviruses, vol. 1, In: Tijssen P (ed). Boca Raton: CRC Press, 1990; 11-30.
70. Schwarz TF, Roggendorf M, Hottentrager B, Stolz W, Schwinn H. Removal of Parvoviral B19 from Contaminated Factor VIII During Fractionation. J Med Virol 1991; 35: 28-31.
71. Huyghe BG, Liu X, Sutjipto S, et al. purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum Gene Ther 1995; 6: 1403-1416.
72. Tamayose K, Hirai Y, Shimada T. A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. Hum Gene Ther 1996; 7: 507-513.
73. Zolotukhin S, et al. Column purification of AAV vectors. Gene Ther 1999; in press.
74. Krieg AM, Yi AK, Schorr J, Davis HL. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol 1998; 6: 23-27.
75. Mah C, Qing K, Khuntirat B, et al. Adeno-associated virus type 2-mediated gene transfer: role of epidermal growth factor receptor protein tyrosine kinase in transgene expression. J Virol 1998; 72: 9835-9843.
76. CBER. Guidence for human somatic cell therapy and gene therapy. Hum Gene Ther 1998; 9: 1513-1524.
77. Kotin RM, Siniscalco M, Samulski RJ, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A 1990; 87: 2211-2215.
78. Yang CC, Xiao X, Zhu X, et al. Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro. J Virol 1997; 71: 9231-9247.
79. Kotin RM, Linden RM, Berns KI. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 1992; 11: 5071-5078.
80. Linden RM, Winocour E, Berns KI. The recombination signals for adeno-associated virus site-specific integration. Proc Natl Acad Sci U S A 1996; 93: 7966-7972.
81. Shelling AN, Smith MG. Targeted integration of transfected and infected adeno-associated virus vectors containing the neomycin resistance gene. Gene Ther 1994; 1: 165-169.
82. Surosky RT, Urabe M, Godwin SG, et al. Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome. J Virol 1997; 71: 7951-7959.
83. Aiyar A, Hindmarsh P, Skalka AM, Leis J. Concerted integration of linear retroviral DNA by the avian sarcoma virus integrase in vitro: dependence on both long terminal repeat termini. J Virol 1996; 70: 3571-3580.
84. Lamartina S, Roscilli G, Rinaudo D, Delmastro P, Toniatti C. Lipofection of purified adeno-associated virus Rep68 protein: toward a chromosome-targeting nonviral particle. J Virol 1998; 72: 7653-7658.
85. Palombo F, Monciotti A, Recchia A, Cortese R, Ciliberto G, La Monica N. Site-specific integration in mammalian cells mediated by a new hybrid baculovirus-adeno-associated virus vector. J Virol 1998; 72: 5025-5034.
86. Urcelay E, Ward P, Wiener SM, Safer B, Kotin RM. Asymmetric replication in vitro from a human sequence element is dependent on adeno-associated virus Rep protein. J Virol 1995; 69: 2038-2046.
87. Linden RM, Ward P, Giraud C, Winocour E, Berns KI. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A 1996; 93: 11288-11294.
88. Snyder RO, Samulski RJ, Muzyczka N. In vitro resolution of covalently joined AAV chromosome ends. Cell 1990; 60: 105-113.
89. Dyall J, Berns KI. Site-specific integration of adeno-associated virus into an episome with the target locus via a deletion-substitution mechanism. J Virol 1998; 72: 6195-6198.
90. Rutledge EA, Russell DW. Adeno-associated virus vector integration junctions. J Virol 1997; 71: 8429-8436.
91. Ponnazhagan S, Erikson D, Kearns WG, et al. Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells. Hum Gene Ther 1997; 8: 275-284.
92. Kearns WG, Afione SA, Fulmer SB, et al. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. Gene Ther 1996; 3: 748-755.
93. Fisher-Adams G, Wong KK, Jr., Podsakoff G, Forman SJ, Chatterjee S. Integration of adeno-associated virus vectors in CD34+ human hematopoietic progenitor cells after transduction. Blood 1996; 88: 492-504.
94. Miao CH, Snyder RO, Schowalter DB, et al. The kinetics of rAAV integration in the liver [letter]. Nat Genet 1998; 19: 13-15.
95. Wu P, Phillips MI, Bui J, Terwilliger EF. Adeno-associated virus vector-mediated transgene integration into neurons and other non-dividing cell targets. J Virol 1998; 72: 5919-5926.
96. Afione SA, Conrad CK, Kearns WG, et al. In vivo model of adeno-associated virus vector persistence and rescue. J Virol 1996; 70: 3235-3241.
97. Duan D, Sharma P, Yang J, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 1998; 72: 8568-8577.
98. Hargrove PW, Vanin EF, Kurtzman GJ, Nienhuis AW. High-level globin gene expression mediated by a recombinant adeno-associated virus genome that contains the 3′ gamma globin gene regulatory element and integrates as tandem copies in erythroid cells. Blood 1997; 89: 2167-2175.
99. Vincent-Lacaze N, Snyder RO, Gluzman R, Bohl D, Lagarde C, Danos O. Structure of adeno-associated virus vector DNA following transduction of the skeletal muscle [In Process Citation]. J Virol 1999; 73: 1949-1955.
100. Weitzman MD, Fisher KJ, Wilson JM. Recruitment, of wild-type and recombinant adeno-associated virus into adenovirus replication centers. J Virol 1996; 70: 1845-1854.
101. Rizzuto G, Gorgoni B, Cappelletti M, et al. Development of animal models for adeno-associated virus site-specific integration [In Process Citation]. J Virol 1999; 73: 2517-2526.
102. Yakobson B, Hrynko TA, Peak MJ, Winocour E. Replication of adeno-associated virus in cells irradiated with UV light at 254 nm. J Virol 1989; 63: 1023-1030.
103. Russell DW, Alexander IE, Miller AD. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci U S A 1995; 92: 5719-5723.
104. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, Wilson JM. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996; 70: 520-532.
105. Qing K, Khuntirat B, Mah C, et al. Adeno-associated virus type 2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo. J Virol 1998; 72: 1593-1599.
106. Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-276.
107. Xiao W, Berta SC, Lu MM, Moscioni AD, Tazelaar J, Wilson JM. Adeno-associated virus as a vector for liver-directed gene therapy. J Virol 1998; 72: 10222-10226.
108. Ponnazhagan S, Mukherjee P, Wang XS, et al. Adeno-associated virus type 2-mediated transduction in primary human bone marrow-derived CD34+ hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation. J Virol 1997; 71: 8262-8267.
109. Flotte T, Carter B, Conrad C, et al. A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 1996; 7: 1145-1159.
110. Wagner JA, Moran ML, Messner AH, et al. A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. Hum Gene Ther 1998; 9: 889-909.
111. Flotte TR, Afione SA, Conrad C, et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci U S A 1993; 90: 10613-10617.
112. Monahan PE, Samulski RJ, Tazelaar J, et al. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther 1998; 5: 40-49.
113. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector [In Process Citation]. Nat Med 1999; 5: 56-63.
114. Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors [In Process Citation]. Nat Med 1999; 5: 64-70.
115. Song S, Morgan M, Ellis T, et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci U S A 1998; 95: 14384-14388.
116. Ponnazhagan S, Yoder MC, Srivastava A. Adeno-associated virus type 2-mediated transduction of murine hematopoietic cells with long-term repopulating ability and sustained expression of a human globin gene in vivo. J Virol 1997; 71: 3098-3104.
117. Zhou S, Murphy JE, Escobedo JA, Dwarki VJ. Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates [In Process Citation]. Gene Ther 1998; 5: 665-670.
118. Kessler PD, Podsakoff GM, Chen X, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A 1996; 93: 14082-14087.
119. During MJ, Samulski RJ, Elsworth JD, et al. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther 1998; 5: 820-827.
120. Bankiewicz KS, Bringas JR, McLaughlin W, et al. Application of gene therapy for Parkinson's disease: nonhuman primate experience. Adv Pharmacol 1998; 42: 801-806.
121. Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994; 8: 148-154.
122. Mandel RJ, Spratt SK, Snyder RO, Leff SE. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci U S A 1997; 94: 14083-14088.
123. Szczypka MS, Mandel RJ, Donahue BA, Snyder RO, Leff SE, Palmiter RD. Viral Gene Delivery Selectively Restores Feeding and Prevents Lethality of Dopamine-deficient Mice. Neuron 1999; 22: 167-178.
124. Klein RL, Meyer EM, Peel AL, et al. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp Neurol 1998; 150: 183-194.
125. Xiao X, McCown TJ, Li J, Breese GR, Morrow AL, Samulski RJ. Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) alpha1 containing receptors and increases inferior collicular seizure sensitivity. Brain Res 1997; 756: 76-83.
126. Mandel RJ, Gage FH, Clevenger DG, Spratt SK, Snyder RO, Leff SE. Nerve growth factor expressed in the medial septum following in vivo gene delivery using a recombinant adeno-associated viral vector protects cholinergic neurons from fimbria-fornix lesion-induced degeneration. Exp Neurol 1999; 155: 59-64.
127. Murphy JE, Zhou S, Giese K, Williams LT, Escobedo JA, Dwarki VJ. Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin. Proc Natl Acad Sci U S A 1997; 94: 13921-13926.
128. Lewin AS, Drenser KA, Hauswirth WW, et al. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nat Med 1998; 4: 967-971.
129. Jomary C, Vincent KA, Grist J, Neal MJ, Jones SE. Rescue of photoreceptor function by AAV-mediated gene transfer in a mouse model of inherited retinal degeneration. Gene Ther 1997; 4: 683-690.
130. Walsh CE, Nienhuis AW, Samulski RJ, et al. Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector [see comments]. J Clin Invest 1994; 94: 1440-1448.
131. Watson GL, Sayles JN, Chen C, et al. Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus. Gene Therapy 1998; 5: 1642-1649.
132. Daly TM, Vogler C, Levy B, Haskins ME, Sands MS. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc Natl Acad Sci U S A 1999; 96: 2296-2300.
133. During MJ, Xu R, Young D, Kaplitt MG, Sherwin RS, Leone P. Peroral gene therapy of lactose intolerance using an adeno-associated virus vector [see comments]. Nat Med 1998; 4: 1131-1135.
134. Qazilbash MH, Xiao X, Seth P, Cowan KH, Walsh CE. Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53. Gene Ther 1997; 4: 675-682.
135. Su H, Lu R, Chang JC, Kan YW. Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepato-cellular carcinoma in athymic mice. Proc Natl Acad Sci U S A 1997; 94: 13891-13896.
136. Mizuno M, Yoshida J, Colosi P, Kurtzman G. Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration. Jpn J Cancer Res 1998; 89: 76-80.
137. Maass G, Bogedain C, Scheer U, et al. Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cells. Hum Gene Ther 1998; 9: 1049-1059.
138. Rendahl KG, Leff SE, Otten GR, et al. Regulation of gene expression in vivo following transduction by two separate rAAV vectors. Nat Biotechnol 1998; 16: 757-761.
139. Bohl D, Salvetti A, Moullier P, Heard JM. Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. Blood 1998; 92: 1512-1517.
140. Ye X, Rivera VM, Zoltick P, et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 1999; 283: 88-91.
141. Haberman RP, McCown TJ, Samulski RJ. Inducible long-term gene expression in brain with adeno-associated virus gene transfer. Gene Ther 1998; 5: 1604-1611.
142. Donahue BA, McArthur J, Spratt SK, et al. Selective uptake and sustained expression of AAV vectors following subcutaneous delivery. J Gene Med 1999; 1: 1-16.
143. Blacklow NR, Hoggan MD, Rowe WP. Serologic evidence for human infection with adenovirus-associated viruses. J Natl Cancer Inst 1968; 40: 319-327.
144. Manning WC, Zhou S, Bland MP, Escobedo JA, Dwarki V. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum Gene Ther 1998; 9: 477-485.
145. Halben CL, Standaert TA, Wilson CB, Miller AD. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J Virol 1998; 72: 9795-9805.
146. Chiorini JA, Yang L, Liu Y, Safer B, Kotin RM. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J Virol 1997; 71: 6823-6833.
147. Snyder RO, Spratt SK, Lagarde C, et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther 1997; 8: 1891-1900.
148. Fisher KJ, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997; 3: 306-312.
149. Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212-4223.